Baker McKenzie with Geistlich on TRI’s stake acquisition
Baker McKenzie advised Swiss medical regeneration technologies specialist Geistlich Pharma (Geistlich) on its acquisition of a minority stake in TRI Dental Implants (TRI), a provider of digital implant solutions which developed an abutment-free dental implant system, allowing crowns to be attached directly to the implant.
The Baker McKenzie team
Partner Alexander Fischer (pictured) led the Baker McKenzie M&A team on the matter, working with partner Matthias Trautmann and associate Hesam Mirzai – all from the firm’s Zurich office.
